Dr. Alberto De Iaco, PhD

Director, Platform Development - Gene and Cell Therapy at Tessera Therapeutics

Speaker

Alberto De Iaco is a Director at Tessera Therapeutics in Boston, USA. Since joining the company in 2021, he has led a team that contributed to the development of Tessera’s RNA Gene Writer platform and its application to engineer CAR-T cells in vivo.Alberto earned his PhD in Microbiology from the University of Geneva, where he investigated the interplay between HIV-1 and host cells during viral infection. He later conducted postdoctoral research at EPFL in Lausanne, focusing on the epigenetic regulation of retrotransposons during embryonic development. Prior to joining Tessera, Alberto worked at bluebird bio in Boston, where he contributed to improving the activity, manufacturing, and safety of lentiviral vectors used in gene therapies for rare genetic diseases.